THERAPY DOSSIER · th-042734c6cf13

Neuroprotectin/protectin D1 (NPD1/PD1), 10R,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25273880 ↗2014Reported benefit

Neuroprotectin/protectin D1: endogenous biosynthesis and actions on diabetic macrophages in promoting wound healing and innervation impaired by diabetes.

MouseWound

Model: Excisional skin wound in diabetic mice, with macrophage depletion and transfer of macrophages isolated from diabetic mice

Injury induced endogenous NPD1 biosynthesis in wounds but diabetes impeded its formation; NPD1 was produced mainly by macrophages. NPD1, and NPD1-modulated diabetic macrophages, enhanced wound healing and innervation in diabetic mice, attenuating macrophage inflammatory activity, chronic inflammati…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…